The Cardiac Amyloidosis Clinic at VGH & SPH is involved in many types of amyloidosis research. Patients attending the clinic may be invited to participate in a study.
Some of our current and recently completed studies are listed below. Please ask your medical team if any clinical trial opportunities are available for you:
Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy (https://clinicaltrials.gov/study/NCT02791230)
Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy (ATTRibute-CM) (https://clinicaltrials.gov/study/NCT03860935)
Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants (https://clinicaltrials.gov/study/NCT04988386)
CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) (https://clinicaltrials.gov/study/NCT04136171)
A Research Study to Look at How a New Medicine Called NNC6019-0001 Works and How Safe it is for People Who Have Heart Disease Due to Transthyretin (TTR) Amyloidosis (https://clinicaltrials.gov/study/NCT05442047)
The Canadian Registry for Amyloidosis Research (CRAR) (http://www.amyloidregistry.ca)
Email: info@amyloidosis.com
Phone: 604 875-5759
Fax: 604 875-4265
St Paul Address:
5 C/D-5th Floor, Providence Building
1081 Burrard Street
Vancouver BC
V6Z 1Y6
VGH Address:
Gordon and Leslie Diamond Health Care Centre
2775 Laurel St., 9th Floor
Vancouver BC
V5Z 1M9
